A Double-blind, Randomized, Shamprocedurecontrolled, Parallel -group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology: DREAM HF-1
| Sponsor: |
Mesoblast Inc. |
| Enrolling: |
Male and Female Patients |
| IRB Number: |
AAAO3307 |
| U.S. Govt. ID: |
NCT02032004 |
| Contact: |
Yonandy Barrientos: 212-305-1368 / caccresearch@cumc.columbia.edu |
In this study, patients with heart failure, will undergo a cardiac catheterization procedure which either includes injections of stem cells from healthy young adults into the heart or a sham (mock) procedure that does not include injection of the stem cells. This is a study of an experimental product called rexlemestrocel-L.
This study is closed
Investigator
Maryjane Farr, MD
| Do you have heart failure? |
Yes |
No |
| Do you have an LVAD or heart transplant? |
Yes |
No |
| Have you ever been in a trial where you received stem cells? |
Yes |
No |